Ultragenyx Pharmaceutical
RARENASDAQRare disease development and commercialization platform spanning biologics, AAV, and small molecules
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
Filing figures as of June 30, 2026 · text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
RARE filings on EDGAR →Cash & investments
$436M
at June 30, 2026 (10-Q)
Quarterly operating burn
$147M
average per quarter, Jan–Jun 2026
Cash runway
~9 months
$436M ÷ $147M per quarter
Shares outstanding
98.6M
cover page of the latest filing
Read from RARE's XBRL financial data; latest filing August 5, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Early revenue.
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
MCE study: Triheptanoin in Long-chain fatty acid oxidation disorders — primary completion
2027-08
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
GTX-301: DTX301 in Late-onset OTC deficiency — primary completion
2027-09
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Crysvita | X-linked hypophosphatemia | Approved | Not disclosed | ▼ |
| UX111 | Sanfilippo syndrome type A | Phase 3 | Not disclosed | ▼ |
| GTX-102 | Angelman syndrome | Phase 2 | Not disclosed | ▼ |
Analysis
Comparable companies
Sponsored
Get premium RARE analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you